Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

Arsalan Rafiq, Tausif Chughtai, Umair Ashraf, Yash Patel, Farbod Raiszadeh, Eduard Sklyar, Maryam Afshar, Jonathan N. Bella, Gayathri Kamalakkannan

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

Original languageEnglish
Pages (from-to)296-298
Number of pages3
JournalIndian Heart Journal
Volume72
Issue number4
DOIs
StatePublished - 1 Jul 2020

Keywords

  • Myocardial perfusion imaging
  • QTc interval prolongation
  • Regadenoson

Fingerprint

Dive into the research topics of 'Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging'. Together they form a unique fingerprint.

Cite this